Background: P27A is an unstructured 104mer synthetic peptide from Plasmodium falciparum trophozoite exported protein 1 (TEX1), the target of human antibodies inhibiting parasite growth. The present project aimed at evaluating the safety and immunogenicity of P27A peptide vaccine in malaria-nonexposed European and malaria-exposed African adults. Methods: This study was designed as a staggered, fast-track, randomized, antigen and adjuvant dose-finding, multicenter phase 1a/1b trial, conducted in Switzerland and Tanzania. P27A antigen (10 or 50 μg), adjuvanted with Alhydrogel or glucopyranosil lipid adjuvant stable emulsion (GLA-SE; 2.5 or 5 μg), or control rabies vaccine (Verorab) were administered intramuscularly to 16 malaria-nonexposed and 40 malaria-exposed subjects on days 0, 28, and 56. Local and systemic adverse events (AEs) as well as humoral and cellular immune responses were assessed after each injection and during the 34-week follow-up. Results: Most AEs were mild to moderate and resolved completely within 48 hours. Systemic AEs were more frequent in the formulation with alum as compared to GLA-SE, whereas local AEs were more frequent after GLA-SE. No serious AEs occurred. Supported by a mixed Th1/Th2 cell-mediated immunity, P27A induced a marked specific antibody response able to recognize TEX1 in infected erythrocytes and to inhibit parasite growth through an antibody-dependent cellular inhibition mechanism. Incidence of AEs and antibody responses were significantly lower in malaria-exposed Tanzanian subjects than in nonexposed European subjects. Conclusions: The candidate vaccine P27A was safe and induced a particularly robust immunogenic response in combination with GLA-SE. This formulation should be considered for future efficacy trials. Clinical Trials Registration: NCT01949909, PACTR201310000683408.
RCT Entities:
Background: P27A is an unstructured 104mer synthetic peptide from Plasmodium falciparum trophozoite exported protein 1 (TEX1), the target of human antibodies inhibiting parasite growth. The present project aimed at evaluating the safety and immunogenicity of P27A peptide vaccine in malaria-nonexposed European and malaria-exposed African adults. Methods: This study was designed as a staggered, fast-track, randomized, antigen and adjuvant dose-finding, multicenter phase 1a/1b trial, conducted in Switzerland and Tanzania. P27A antigen (10 or 50 μg), adjuvanted with Alhydrogel or glucopyranosil lipid adjuvant stable emulsion (GLA-SE; 2.5 or 5 μg), or control rabies vaccine (Verorab) were administered intramuscularly to 16 malaria-nonexposed and 40 malaria-exposed subjects on days 0, 28, and 56. Local and systemic adverse events (AEs) as well as humoral and cellular immune responses were assessed after each injection and during the 34-week follow-up. Results: Most AEs were mild to moderate and resolved completely within 48 hours. Systemic AEs were more frequent in the formulation with alum as compared to GLA-SE, whereas local AEs were more frequent after GLA-SE. No serious AEs occurred. Supported by a mixed Th1/Th2 cell-mediated immunity, P27A induced a marked specific antibody response able to recognize TEX1 in infected erythrocytes and to inhibit parasite growth through an antibody-dependent cellular inhibition mechanism. Incidence of AEs and antibody responses were significantly lower in malaria-exposed Tanzanian subjects than in nonexposed European subjects. Conclusions: The candidate vaccine P27A was safe and induced a particularly robust immunogenic response in combination with GLA-SE. This formulation should be considered for future efficacy trials. Clinical Trials Registration: NCT01949909, PACTR201310000683408.
Authors: Steven G Reed; Darrick Carter; Corey Casper; Malcolm S Duthie; Christopher B Fox Journal: Semin Immunol Date: 2018-10-23 Impact factor: 11.130
Authors: Danika L Hill; Wim Pierson; Daniel J Bolland; Catherine Mkindi; Edward J Carr; Jiong Wang; Sophie Houard; Steven W Wingett; Regine Audran; Elizabeth F Wallin; Said A Jongo; Kassim Kamaka; Martin Zand; Francois Spertini; Claudia Daubenberger; Anne E Corcoran; Michelle A Linterman Journal: J Exp Med Date: 2019-06-07 Impact factor: 14.307
Authors: David Ricardo Salamanca; Marcela Gómez; Anny Camargo; Laura Cuy-Chaparro; Jessica Molina-Franky; César Reyes; Manuel Alfonso Patarroyo; Manuel Elkin Patarroyo Journal: Front Microbiol Date: 2019-12-03 Impact factor: 5.640
Authors: Catherine Gerald Mkindi; Elias Antony Marandu; Ngisi Masawa; Farida Bani; Amina Nyuri; Theonestina Byakuzana; Thomas Klimkait; Song Ding; Giuseppe Pantaleo; Manuel Battegay; Nina Orlova-Fink; Maja Weisser-Rohacek; Claudia Daubenberger Journal: BMC Res Notes Date: 2019-09-06
Authors: Kristina M Geiger; Daniel Guignard; Che Yang; Jean-Pierre Bikorimana; Bruno E Correia; Sophie Houard; Catherine Mkindi; Claudia A Daubenberger; François Spertini; Giampietro Corradin; Régine Audran Journal: Front Immunol Date: 2020-03-10 Impact factor: 7.561
Authors: Alexander Gunn; Shashika Bandara; Gavin Yamey; Flavia D Alessio; Hilde Depraetere; Sophie Houard; Nicola K Viebig; Stefan Jungbluth Journal: F1000Res Date: 2019-07-11